Clover Biopharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3.51	38.42	39.26	-	-
Revenue Growth (YoY)	-90.88%	-2.13%	-	-	-
Cost of Revenue	0.2	711.36	1,712	475.64	66.27
Gross Profit	3.31	-672.94	-1,673	-475.64	-66.27
Selling, General & Admin	71.4	94.88	253.58	410.24	345.71
Research & Development	182.34	183.39	649.89	1,465	1,826
Other Operating Expenses	4.46	3.63	24.59	49.01	0.43
Operating Expenses	258.2	281.9	928.05	1,925	2,172
Operating Income	-254.89	-954.84	-2,601	-2,400	-2,239
Interest Expense	-0.38	-5.76	-18.72	-5.93	-8.22
Interest & Investment Income	6.33	23.69	16.12	8.51	10.89
Currency Exchange Gain (Loss)	11.46	-23.85	-34.98	-25.41	10.35
Other Non Operating Income (Expenses)	36.13	16.58	12.43	14.51	16.11
EBT Excluding Unusual Items	-201.35	-944.19	-2,626	-2,409	-2,210
Merger & Restructuring Charges	-	-	-	-13.84	-
Gain (Loss) on Sale of Investments	0.17	0.4	-	0.23	0.91
Gain (Loss) on Sale of Assets	-0.01	2	-4.74	-8.43	-
Asset Writedown	-	-14.01	-10.31	-	-
Other Unusual Items	-3.9	52.37	2,503	-21.32	-3,808
Pretax Income	-205.09	-903.43	-138.54	-2,452	-6,016
Net Income	-205.09	-903.43	-138.54	-2,452	-6,016
Net Income to Common	-205.09	-903.43	-138.54	-2,452	-6,016
Shares Outstanding (Basic)	1,260	1,254	1,244	1,102	1,158
Shares Outstanding (Diluted)	1,260	1,254	1,244	1,102	1,158
Shares Change (YoY)	0.53%	0.82%	12.83%	-4.84%	52.85%
EPS (Basic)	-0.16	-0.72	-0.11	-2.22	-5.19
EPS (Diluted)	-0.16	-0.72	-0.11	-2.22	-5.19
Free Cash Flow	-194.86	-289.62	-734.83	-1,768	-977
Free Cash Flow Per Share	-0.15	-0.23	-0.59	-1.60	-0.84
Gross Margin	94.29%	-	-	-	-
Operating Margin	-7272.18%	-2485.33%	-6626.46%	-	-
Profit Margin	-5851.41%	-2351.51%	-352.92%	-	-
Free Cash Flow Margin	-5559.46%	-753.84%	-1871.94%	-	-
EBITDA	-237.82	-926.43	-2,563	-2,371	-2,226
D&A For EBITDA	17.07	28.41	38.3	28.98	12.29
EBIT	-254.89	-954.84	-2,601	-2,400	-2,239

Source: S&P Global Market Intelligence. Standard template. Financial Sources.